Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Cancer Discov. 2020 Jun 30;10(11):1672–1689. doi: 10.1158/2159-8290.CD-20-0226

Figure 7. Proposed model of PARG inhibition combined with TMZ in IDH mutant cancer cells.

Figure 7.

Low basal NAD+ levels in IDH mutant cancer cells, combined with sequestration of NAD+ as PAR by temozolomide (TMZ) + PARG inhibitor (PARGi), lead to metabolic catastrophe and cell death.